Skip to main content
. 2024 May 16;120(12):1400–1410. doi: 10.1093/cvr/cvae109

Figure 1.

Figure 1

Study design. aPatients from ORION-3 did not receive any drug administration on Day 1. Only patients on placebo in ORION-9, ORION-10, and ORION-11 received an active inclisiran injection at Day 1, while patients who received inclisiran in those trials received blinded placebo at this visit; bEOS is either day 1080 or ≥ 90 days following the last dose of inclisiran. D, Day; EOS, end-of-study.